ProBio Enters Exclusive Licensing Agreement with AbTis for Next-Gen ADC Development

HOPEWELL, N.J., Nov. 10, 2026 /CourierPR/ -- ProBio Inc., a global contract research, development, and manufacturing organization (CRDMO), has entered into an exclusive global licensing agreement with AbTis Co., Ltd., a South Korean biotechnology company and subsidiary of Dong-A ST, to develop a next-generation antibody-drug conjugate (ADC) asset.

Under the agreement, AbTis will leverage its proprietary AbClick® site-specific conjugation platform to expand its pipeline in bispecific antibody-drug conjugates. The asset was generated through ProBio's biologics discovery and development capabilities against an oncology target. This collaboration aims to advance the therapeutic antibody toward the development of a next-generation ADC, potentially improving treatment outcomes for patients with cancer.

The AbClick® platform, developed by AbTis, is designed to enable controlled, site-specific antibody conjugation. This approach is intended to improve the consistency and characteristics of ADCs compared to conventional nonspecific conjugation methods. AbTis is advancing its technology across oncology applications, aiming to develop next-generation bioconjugate therapeutics that can improve treatment outcomes for patients with cancer and other serious diseases.

The agreement includes an upfront payment to ProBio, as well as potential developmental and commercial milestone payments and royalties on future sales. This transaction highlights ProBio's growing role in creating differentiated biologics assets and enabling innovative drug development through the combination of discovery expertise, advanced biologics platforms, and development and manufacturing capabilities.

ProBio Inc. is a global CRDMO enabling biotech and pharmaceutical companies to advance the development and manufacturing of next-generation therapies. With expertise across biologics, cell and gene therapy, ProBio delivers integrated development and manufacturing solutions spanning antibodies, mRNA, plasmid DNA, viral vectors, and in vivo CAR-T therapies. The company's scalable, GMP-compliant platforms support partners from early discovery through commercial manufacturing, helping accelerate timelines and de-risk complex development programs.

Through a collaborative partnership approach, ProBio works closely with customers to advance programs from scientific development through regulatory and commercial milestones. This agreement further reinforces ProBio's commitment to enabling its partners to build a differentiated pipeline of innovative biologics assets.